CHCHD2 and EGFR protein expression in NSCLC

Slides:

Advertisements

Similar presentations

Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.

Advertisements

PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Enhanced DNA damage in IDH1 mutant glioma cells.

KDM1B Expression in Richardson Breast 2

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

The cBio Cancer Genomics Portal.

CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer Kit W. Tam, MD, MHS,

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Genomic alterations in breast cancer cell line MDA-MB-231.

Intrinsic and acquired trastuzumab resistance.

A. glioblastoma with high (+++) KIT protein expression.

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Volume 24, Issue 12, Pages e5 (September 2018)

Bar plot representation of the transcriptomic changes in Δsaci_ptp and Δsaci_pp2a. Bar plot representation of the transcriptomic changes in Δsaci_ptp and.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Changes in mutation rate or protein abundance are not observed in HATs when comparing rho+ to rho0 cells. Changes in mutation rate or protein abundance.

NRG1 rearrangements are found in multiple solid tumors.

TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Representative Western blot analyses of S-phase and other proteins from PC3 cell lysates obtained 3 days after oligomer (400 nm)/Lipofectin (15 μg/ml)

FOXO3a phosphorylation and expression.

A, PTEN loss signature score in resected SQCLC brain metastases.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Integrated mRNA and microRNA expression and DNA methylation clusters.

MAPJD expression in lung cancers.

EGFR and cetuximab sensitivity of SCCUAT

Ki-67 expression is determined by the cell-cycle stage.

VEGF expression in neoplastic and normal prostate tissue.

Active AR signaling in enzalutamide-resistant xenograft tumors.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

Expression pattern of TLR-4 and MyD88 in EOC cells.

Activation of mTOR signaling (increased phosphorylated S6 ribosomal protein) and loss of inhibition of IRS-1 in human endometrial carcinomas. Activation.

Generation and characterization of LSCCs generated by Trp53−/− and Keap1−/−;Trp53−/− tracheal epithelial cells. Generation and characterization of LSCCs.

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Pirh2 represses p73-dependent transactivation.

SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression. SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression.

Number of identical D-loop DNA clones detected in 10 DNA clones derived from liver tumor tissues. Number of identical D-loop DNA clones detected in 10.

Characterization of DNA-PK and PARP-1 levels and activities in the cell lines studied. Characterization of DNA-PK and PARP-1 levels and activities in the.

Location of the ER mutations and frequencies per cohort.

Combined inhibition of coamplified RTKs is required for response.

Frequent coamplification of RTKs in MET-amplified EGC

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

Frequently mutated genes in colorectal cancer.

Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Validation of NAA's cancer specificity in lung cancer.

Immune profiling of patient-derived organotypic tumor spheroids.

A and B, linearity of the preamplification step shown by a similar expression pattern of ERα mRNA in four breast tumor samples pre– and post–linear amplification.

Identification of RASA1- and NF1-mutated lung cancer cell lines in the CCLE dataset (accessed via the cBioPortal for Cancer Genomics at

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Expression of chemokine receptors in A-498 cell line.

Germline variants influencing primary tumor type.

A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

Gene expression heatmap of non–T-cell-inflamed, intermediate, and T-cell–inflamed testicular germ cell tumors from TCGA. Genes are on the row, and samples.

Superenhancers near the KLF5 gene are focally amplified in diverse cancer types. Superenhancers near the KLF5 gene are focally amplified in diverse cancer.

mRNA expression of PARP1 in SCLC cell lines and solid tumors.

The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.

CASP8 mutations are associated with fewer CNAs and RAS family mutations. CASP8 mutations are associated with fewer CNAs and RAS family mutations. A, number.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Loss of NQO1 expression inhibits invasion of NSCLC

Proteome changes associated with CHCHD2 expression in NSCLC cells.

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

BRAF in-frame deletions mainly function as BRAF homodimers.

Presentation transcript:

CHCHD2 and EGFR protein expression in NSCLC CHCHD2 and EGFR protein expression in NSCLC. A, amplification of EGFR and CHCHD2 genes in NSCLC subtypes. CHCHD2 and EGFR protein expression in NSCLC. A, amplification of EGFR and CHCHD2 genes in NSCLC subtypes. Shown are OncoPrint outputs (cBioPortal for Cancer Genomics; www.cbioportal.org) where each bar represents a tumor that was found to contain a DNA alteration (amplification, deletion, mutation, as indicated) in EGFR and CHCHD2 in the indicated NSCLC subtypes; note that aligned bars represent the same tumor. Data for LADC and LSCC are from TCGA resource, obtained through cBioPortal. For LADC, 40 of 230 cases (17%) contained a DNA alteration in the EGFR gene, while the incidence for CHCHD2 was 7%. In 13 of 15 cases, the genes were coamplified; odds ratio = 101.8, indicating a strong tendency toward cooccurrence of EGFR and CHCHD2 amplification. For LSCC 16 of 178 cases (9%) contained EGFR amplification or mutation, and an equal number of cases (13) contained amplification of both EGFR and CHCHD2. Odds ratio = infinite, indicating a strong tendency toward cooccurrence of EGFR and CHCHD2 amplification. EGFR as expected, but not CHCHD2, is in some instances mutated in addition to being amplified, as indicated by the green features. B, LC/MS-MS analysis of 11 human tumor-derived NSCLC xenografts (as indicated; A, adenocarcinoma; S, squamous cell carcinoma). C, EGFR and CHCHD2 expression were highly correlated as indicated by correlation of determination analysis (R2), as indicated. After removing sample S3 that was the only sample with a cytogenetically defined amplification of EGFR/7p11.2, the two proteins remained moderately correlated in their expression level (R2 = 0.35). D, Western blot analysis of CHCHD2 and EGFR expression in HEK293 cells (control), or this cell type stably expressing ectopic EGFR (EGFR). Transferrin receptor (TfR) was detected as an input control. Yuhong Wei et al. Mol Cancer Res 2015;13:1119-1129 ©2015 by American Association for Cancer Research